Karyopharm Therapeutics Inc (KPTI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Karyopharm Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 13 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.00 $ — 1% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
Uses AIKaryopharm setzt generative KI-Werkzeuge fuer interne Produktivitaet ein (Entwuerfe, Stellenausschreibungen), erzielt damit aber keinen KI-Umsatz und trifft ausdruecklich keine autonomen KI-Entscheidungen in der klinischen Entwicklung.
View the full file — quotes, sources, reviewed filings
„We use and integrate artificial intelligence (“AI”) into our business processes, such as generative AI tools, primarily to support internal productivity activities, including drafting documents, job postings, and other non-clinical, non-operational materials."
Wir setzen kuenstliche Intelligenz („KI“) in unseren Geschaeftsprozessen ein und integrieren sie, etwa generative KI-Werkzeuge, vor allem zur Unterstuetzung interner Produktivitaet — darunter das Verfassen von Dokumenten, Stellenausschreibungen und anderen nicht-klinischen, nicht-operativen Materialien.
„We do not use our AI systems to make autonomous decisions related to clinical development, patient care, biometrics, pricing, credit, employment decisions, or other regulated or sensitive activities."
Wir nutzen unsere KI-Systeme nicht, um autonome Entscheidungen in Bezug auf klinische Entwicklung, Patientenversorgung, Biometrie, Preisgestaltung, Kreditvergabe, Beschaeftigungsfragen oder andere regulierte oder sensible Taetigkeiten zu treffen.
Filings Reviewed: 10-K 2026-02-13 · 10-Q 2026-05-14
Rated on July 10, 2026 · How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -2.4% failed
- More than 10% revenue growth is expected for the coming year 13.2% passed
- Share count grows by less than 3% a year 26.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -51.0% failed
- Gross margin at 40% or higher and without meaningful erosion 95.9% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 120 m failed
- Return on capital at 15% or higher, or up versus two years ago -554.6% failed
- Insiders hold at least 10% or are net buyers 4.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 575.0% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -1.25 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.36 | – | 31 | -9.50 | -100.80 | -26 | -26 |
| 2025: Q1 | -1.04 | – | 30 | -9.40 | -78.20 | -39 | -39 |
| 2025: Q2 | -1.64 | -256.60 | 38 | -11.40 | -98.20 | -19 | -19 |
| 2025: Q3 | -1.46 | – | 44 | 13.60 | -75.20 | -6 | -6 |
| 2025: Q4 | -4.51 | – | 34 | 11.60 | -299.90 | -12 | -12 |
| 2026: Q1 | -0.99 | – | 35 | 16.80 | -63.90 | -23 | -23 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Karyopharm Therapeutics Inc., ein Pharmaunternehmen in der Vermarktungsphase, entdeckt, entwickelt und vermarktet Medikamente, die gegen den nukleären Export gerichtet sind, zur Behandlung von Krebs und anderen Erkrankungen in den USA.
| Employees | 228 |
|---|---|
| Headquarters | Newton, MA |
| Website | karyopharm.com |
| IPO Date | 6. Nov 2013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Richard A. Paulson M.B.A. | President, CEO & Director | 1967 |
| Stuart Poulton | Executive VP & Chief Development Officer | 1973 |
| Reshma Rangwala M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Research | 1978 |
| Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1970 |
| Lori A. Macomber CPA | EVP, CFO & Treasurer | 1971 |
| Kristin Abate | VP, Chief Accounting Officer & Assistant Treasurer | – |
| Brendan Twohig Strong | Senior Vice President of Investor Relations | – |
| Michael J. Mano J.D. | Executive VP, Chief Legal Officer & Secretary | 1977 |
| James Accumanno J.D. | Chief Compliance Officer | – |
| Lisa DiPaolo | Executive VP & Chief Human Resource Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 28. Jul 2026 | Poulton Stuart | EVP, Chief Development Officer | Sell | 189 | 7.10 | 1,342 |
| 21. Apr 2026 | Reshma Rangwala | EVP | Sell | 449 | 8.94 | 4,014 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.